Device attaches directly to damaged heart, enabling delivery of multiple therapy doses

June 11, 2018, Massachusetts Institute of Technology
'Therepi' device attaches to heart
Therepi's reservoir, which would attach directly to the damaged heart tissue, is placed on a dime for size reference and connected to a self-sealing subcutaneous port. Credit: Nature Biomedical Engineering, Whyte et al.

After a patient has a heart attack, a cascade of events leading to heart failure begins. Damage to the area in the heart where a blood vessel was blocked leads to scar tissue. In response to scarring, the heart will remodel to compensate. This process often ends in ventricular or valve failure.

A team of researchers is hoping to halt the progression from attack to with a small device called 'Therepi.' The device contains a reservoir that attaches directly to the damaged heart tissue. A refill line connects the reservoir to a port on or under the patient's skin where therapies can be injected either by the patient or a healthcare professional.

A new study published in Nature Biomedical Engineering involving a team of researchers from MIT, Harvard University, Royal College of Surgeons in Ireland, Trinity College Dublin, Advanced Materials and BioEngineering Research (AMBER) Centre, and National University of Ireland Galway details how Therepi can be used to restore cardiac function.

"After a we could use this device to deliver therapy to prevent a patient from getting heart failure," explains Ellen Roche, co-first author of the study and assistant professor at MIT's Department of Mechanical Engineering and MIT's Institute for Medical Engineering and Science. "If the patient already has some degree of heart failure, we can use the device to attenuate the progression."

Two of the most common systems currently used for delivering therapies to prevent heart failure are inefficient and invasive. In one method, drugs are delivered systemically rather than being administered directly to the site of the damage. The volume of drugs used has to be limited to avoid toxic side effects and often only a small amount reaches the damaged heart tissue.

"From a pharmacological point-of-view, it's a big problem that you're injecting something that doesn't stay at the damaged tissue long enough to make a difference," says William Whyte, co-first author and Ph.D. candidate at Trinity College Dublin and AMBER.

The alternative method involves an invasive procedure to directly inject therapies into the heart muscle. Since multiple doses are needed, this requires multiple invasive surgeries.

Therepi looks like a small patch and can be sutured onto tissue, in this case, a heart. Credit: Second Bay Studios/Harvard SEAS

Therepi addresses the problems with current drug delivery methods by administering localized, non-invasive therapies as many times as needed. The device's reservoir can be implanted on the heart in just one surgical procedure.

Localized, bespoke therapies

The reservoir itself holds amazing potential for drug delivery. Constructed out of a gelatin-based polymer, the reservoir has a half-spherical shape with a flat bottom attached to the diseased tissue. The flat bottom consists of a semi-permeable membrane that can be adjusted to allow more drugs or larger materials to pass directly into the heart tissue.

"The material we used to construct the reservoir was crucial. We needed it to act like a sponge so it could retain the therapy exactly where you need it," adds Whyte. "That is difficult to accomplish since the heart is constantly squeezing and moving."

The reservoir provides a unique opportunity for administering stem cell therapies. It acts as a cell factory. Rather than pass through the membrane into the heart, the cells stay within the reservoir where they produce paracrine factors that promote healing in the damaged .

In a rat model, the device was shown to be effective in improving cardiac function after a heart attack. The researchers administered multiple doses of cells to a damaged heart throughout a four-week period. They then analyzed the hemodynamic changes in the tissue using a pressure volume catheter and used echocardiography to compare functional changes over time.

Therepi's reservoir can be connected to a port or pump via a tube when it needs to be refilled. Credit: Second Bay Studios/Harvard SEAS
"We saw that the groups that had our device had recovered some heart function," explains Claudia Varela, a Ph.D. student in the Harvard-MIT Division of Health Sciences and Technology.

The hearts that received multiple dosages of cells via had more than those who received only a single injection or no treatment at all.

Finding the Optimal Dose

Therepi's capabilities go beyond treating heart disease. Since it provides the opportunity for multiple, localized doses to be delivered, it could be used as a tool to identify the exact dosage appropriate for a host of conditions.

"We are hoping to use the device itself as a research tool to learn more about the optimal drug loading regime," says Roche.

For the first time, researchers could have an opportunity to track multiple refills of localized therapies over time to help identify the best dosing intervals and dose amount.

"As a pharmacist by training, I'm really excited to start investigating what the best dose is, when is the best time to deliver after a heart attack, and how many doses are needed to achieve the desired therapeutic effect," adds Whyte.

While the team has been focusing on how Therepi can mitigate the effects of heart disease, the device could be used in other parts of the body. By optimizing the design and adjusting the materials used to construct the reservoir, Therepi could be used for a wide range of diseases and health problems.

"The is really a platform that can be tailored to different organ systems and different conditions," says Varela. "It's just a great example of how intersectional research looking at both devices and biological therapies can help us come up with new ways to treat disease."

Explore further: Investigational heart failure therapy seeks to stimulate body's natural healing response

More information: Sustained release of targeted cardiac therapy with a replenishable implanted epicardial reservoir, Nature Biomedical Engineering (2018). DOI: 10.1038/s41551-018-0247-5 , https://www.nature.com/articles/s41551-018-0247-5

Related Stories

Investigational heart failure therapy seeks to stimulate body's natural healing response

May 2, 2018
The University of Minnesota is the first institution in the state to participate in the phase III clinical trial for CardiAmp Therapy. Previous clinical studies of this therapy have been promising and have shown improvements ...

Vitamin D may help prevent heart failure after heart attack

March 8, 2018
New research has shown how vitamin D may help protect heart tissue and prevent heart failure after a heart attack, potentially offering a low-cost addition to existing treatments for heart failure.

New study finds knocking out p63 gene as means of converting scar tissue into muscle tissue in the heart

April 17, 2018
Following a heart attack, the parts of the heart muscle that die do not regenerate into new heart tissue and instead are replaced by scar tissue. Using rodent models, researchers at Baylor College of Medicine are looking ...

Extreme makeover of the heart: Matrix therapy is first FDA-approved procedure of its kind

September 17, 2015
A cardiovascular team at University of Utah Hospital has successfully performed a first-in-the-world heart procedure on a 72-year-old attorney after suffering a large heart attack. Amit N. Patel, M.D. M.S., director of clinical ...

Linking heart attack damage to the spleen and kidney, an integrated study of heart failure

November 15, 2017
Heart failure after a heart attack is a global epidemic leading to chronic heart failure pathology. About 6 million people in the United States and 23 million worldwide suffer from this end-stage disease.

Stem cell patch shows early promise in treating heart failure

April 5, 2017
Patching a damaged heart with a patient's own muscle stem cells improves symptoms of heart failure, according to a Phase I clinical trial reported in Journal of the American Heart Association, the Open Access Journal of the ...

Recommended for you

Increasing statins dose and patient adherence could save more lives

December 7, 2018
Thousands of heart attacks and deaths from cardiovascular disease could be prevented by patients taking higher doses of statins and taking the drugs as advised by doctors.

Progress made in transplanting pig hearts into baboons

December 6, 2018
A large team of researchers from several institutions in Germany, Sweden, Switzerland and the U.S. has transplanted pig hearts into baboons and kept them alive for an extended period of time. In their paper published in the ...

Obesity ups survival in heart failure, but that's no reason to pile on pounds

December 6, 2018
(HealthDay)—Obese people with heart failure may live longer than those who are thinner—especially if they are "metabolically healthy," a new study suggests.

New genetic insight could help treat rare debilitating heart and lung condition

December 6, 2018
The largest study of genetic variation in patients with pulmonary arterial hypertension has associated two important genes with the disease.

New drug target discovered for potential blood pressure treatment

December 5, 2018
Scientists have identified a key player in blood pressure regulation and have shown that switching it off reduces blood pressure in mice, according to new research in eLife.

Neighborhoods with more green space may mean less heart disease

December 5, 2018
People who live in leafy, green neighborhoods may have a lower risk of developing heart disease and strokes, according to new research published in the Journal of the American Heart Association, the Open Access Journal of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.